Senior Management of Progenics Pharmaceuticals to Webcast Discussion of Phase
2 Data From Two Trials in Prostate Cancer
Webcast Will Take Place Following Poster Presentations at the Annual American
Society of Clinical Oncology Genitourinary Meeting in San Francisco, CA on
January 30th 7PM PST/10PM EST
TARRYTOWN, N.Y., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX), an oncology company focused on the development of
innovative approaches to targeting and treating prostate cancer, will webcast
a discussion of phase 2 data from two of its PSMA targeting late stage
prostate cancer compounds. The discussion will cover 1404, its prostate cancer
imaging agent, and PSMA ADC, its antibody drug conjugate therapeutic agent.
Speakers will include Mark R. Baker, CEO, Hagop Youssoufian, M.D., Executive
Vice President, Research and Development and Robert J. Israel, M.D., Executive
Vice President, Medical Affairs.
The live webcast will be available in the Events section of the Progenics
website, www.progenics.com/events.com. To ensure a timely connection, users
should register at least 15 minutes prior to the scheduled start. An archive
of the event will be available for 90 days.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development. Progenics' first-in-class PSMA targeted
technology platform includes an antibody drug conjugate therapeutic and a
small molecule targeted imaging agent, both completing phase 2 clinical
trials. Among other assets in its pipeline of targeted radiotherapy and
molecular imaging compounds is Azedra^™, an ultra-orphan radiotherapy
candidate in a registrational phase 2 study under an SPA with the FDA.
Progenics' first commercial product, Relistor^® (methylnaltrexone bromide) for
opioid-induced constipation, is partnered with and marketed by Salix
Pharmaceuticals, Inc. Ono Pharmaceutical Co. has licensed subcutaneous
Relistor in Japan. For additional information, please visit www.progenics.com.
This release may contain projections and other forward-looking statements
regarding future events. Such statements are predictions only, and are subject
to risks and uncertainties that could cause actual events or results to differ
materially. These risks and uncertainties include, among others, the cost,
timing and results of clinical trials and other development activities; the
unpredictability of the duration and results of regulatory review of New Drug
Applications and Investigational NDAs; market acceptance for approved
products; generic and other competition; the possible impairment of, inability
to obtain and costs of obtaining intellectual property rights; and possible
safety or efficacy concerns, general business, financial and accounting
matters, litigation and other risks. More information concerning Progenics and
such risks and uncertainties is available on its website, and in its press
releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this release as of its
date and does not undertake any obligation to update or revise it, whether as
a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
For more information, please visit www.progenics.com.
CONTACT: Progenics Pharmaceuticals:
Director, Corporate Development
Press spacebar to pause and continue. Press esc to stop.